Loading…
Shandra Eisenga Human Cell and Tissue Product Safety Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
92pct
138d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Shandra Eisenga Human Cell and Tissue Product Safety Act This bill establishes civil penalties for violations of regulations governing the donation and handling of human cell and tissue products. It also requires the Food and Drug Administration (FDA) to report on the regulation of these products and to provide related information to stakeholders. ( Human cell and tissue products are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.) Specifically, the bill establishes civil penalties for violations of the FDA’s regulations on donor eligibility and current good tissue practice for manufacturing and distributing human cell and tissue products. Also, the bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion on the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and report to Congress with recommendations. The bill also requires the FDA to support the development of educational materials for health care professionals regarding organ, tissue, and eye donations and related topics. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group (a working group within the FDA) and best practices for obtaining a recommendation from them about human cell and tissue products. Also, annually for three years, the FDA must publish on its website information on inquiries submitted to the Tissue Reference Group and FDA registrations and inspections regarding human cell and tissue manufacturers.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Science/Technology
Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding, including the Department of Energy Genesis Mission, and Department of Energy and National Nuclear Security Administration computational research Issues pertaining to science and security, including research security engagements with the Department of Defense/Department of War H.R. 3838/S. 2296 - 2026 National Defense Authorization Act (P.L. 119-60) H.R. 8800/S. 4784 - National Defense Authorization Act for FY27 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue Proposed revisions to 2 CFR Part 200 (Uniform Guidance) H.R. 10574 - American Leadership in Fusion Act Future of Ultra-Intense Laser Science Research and User Facilities
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)
DEBATE - The House proceeded with forty minutes of debate on H.R. 1082.
Considered under suspension of the rules. (consideration: CR H2860-2862)
Mr. Bilirakis moved to suspend the rules and pass the bill.
Placed on the Union Calendar, Calendar No. 127.
Reported by the Committee on Energy and Commerce. H. Rept. 119-160.
Congress.gov source codes: 5000, H12200
Ordered to be Reported by Voice Vote.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $150,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2026 · second_quarter · Science/Technology
Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding, including the Department of Energy Genesis Mission Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue Proposed revisions to 2 CFR Part 200 (Uniform Guidance)
Client expense: $150,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2026 · first_quarter · Science/Technology
Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding, including the Department of Energy Genesis Mission Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue
Client expense: $190,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), Energy, Dept of, HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2025 · fourth_quarter · Science/Technology
Proposed cap of 15% on F&A expenditures (NIH, NSF, DoD, DOE) and the FAIR Model as the proposed alternative developed by a group of Subject Matter Experts as well as higher education and research advocacy associations Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act SAFE Research Act Discussion of proposals that would impact the Bayh-Dole Act, including related impact on university technology transfer programs, and university licensing revenue
Client expense: $150,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2025 · third_quarter · Science/Technology
NIH's proposed cap of 15% on F&A expenditures Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety Securing American Funding and Expertise from Adversarial Research Exploitation Act of 2025 BIOSECURE Act
Client expense: $160,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2025 · third_quarter · Medical/Disease Research/Clinical Labs
H.R. 1 One Big Beautiful Bill Act; S.1882, H.R.3589 RESTORE Act; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care Improvement Act of 2025; H.R.2075, S.987 Protecting Life and Integrity in Research Act of 2025; S.1630, H.R.3235 More Opportunity for Moms to Succeed Act; H.R.4131, S.2172 Respectful Treatment of Unborn Remains Act of 2025; H.R. 685 Support and Value Expectant Moms and Babies Act; Emergency Medical Treatment and Active Labor Act; Dismemberment Abortion Ban Act; IVF Issues; Administration Personnel and Judicial Nominees; Presidential Administration Actions
Client expense: $360,000 · Firm income: Not reported
2025 · third_quarter · Science/Technology
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act HR 5304, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · second_quarter · Family issues/Abortion/Adoption
H.R. 1 One Big Beautiful Bill Act; S.1756, H.R.3411 Conscience Protection Act; H.R.2557 IVF For Military Families Act; S.2035 Protect IVF Act; S.1882, H.R.3589 RESTORE Act; S.J.Res. 56, H.J.Res.98 Life Month; H.R.3287 Pregnancy.Gov Act; S.1384, H.R. 2779 Abortion Funding Awareness Act; H.R. 2706 Aid Accountability Act of 2025; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care Improvement Act of 2025; S.1834, H.R.3762 Supporting Healthy Moms and Babies Act; H.R. 589, S. 223 FACE Act Repeal of 2025; H.R.2075, S.987 Protecting Life and Integrity in Research Act of 2025; H.R.21, S. 6 Born-Alive Abortion Survivors Protection Act; Shield Laws; H.R. 1104, S. 230 Unborn Child Support; Unborn Child Tax Credit; S.1630, H.R.3235 More Opportunity for Moms to Succeed Act; H.R.4131, S.2172 Respectful Treatment of Unborn Remains Act of 2025; S.2150, H.R. 12 Womens Health Protection Act; H.R. 685 Support and Value Expectant Moms and Babies Act; Chemical abortion drugs; H.R. 7, S. 186 No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025; Emergency Medical Treatment and Active Labor Act; Dismemberment Abortion Ban Act; Supporting Pregnant and Parenting Women and Families Act; S.178, H.R.627 Ensuring Accurate and Complete Abortion Data Reporting Act of 2025; Abortion Funding; Contraception Issues; IVF Issues; H.R. 353, S.1382 Family First Act; National Defense Authorization Act; H.R.271 Defund Planned Parenthood Act; S. 203 Defund Planned Parenthood Act; Supreme Court Decisions; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; S. 1631 Restoring Safeguards for Dangerous Abortion Drugs Act; S.242 Dignity for Aborted Children Act; Administration Personnel and Judicial Nominees; Presidential Administration Actions
2025 · second_quarter · Health Issues
H.R. 1 One Big Beautiful Bill Act; S.1756, H.R.3411 Conscience Protection Act; S.1882, H.R.3589 RESTORE Act; H.R.3287 Pregnancy.Gov Act; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care Improvement Act of 2025; S.1834, H.R.3762 Supporting Healthy Moms and Babies Act; H.R. 589, S. 223 FACE Act Repeal of 2025; H.R.21, S. 6 Born-Alive Abortion Survivors Protection Act; Shield Laws; S.1630, H.R.3235 More Opportunity for Moms to Succeed Act; H.R.4131, S.2172 Respectful Treatment of Unborn Remains Act of 2025; S.2150, H.R. 12 Womens Health Protection Act; H.R. 685 Support and Value Expectant Moms and Babies Act; H.R. 7, S. 186 No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025; Emergency Medical Treatment and Active Labor Act; Dismemberment Abortion Ban Act; S.178, H.R.627 Ensuring Accurate and Complete Abortion Data Reporting Act of 2025; Contraception Issues; National Defense Authorization Act; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; S.242 Dignity for Aborted Children Act; Administration Personnel and Judicial Nominees; Presidential Administration Actions
Client expense: $490,000 · Firm income: Not reported
2025 · second_quarter · Medical/Disease Research/Clinical Labs
H.R. 1 One Big Beautiful Bill Act; S.1882, H.R.3589 RESTORE Act; H.R. 1082 Shandra Eisenga Human Cell and Tissue Product Safety Act; HR 1909 Preventing Maternal Deaths Reauthorization Act of 2025; H.R.1418 Purchased and Referred Care Improvement Act of 2025; H.R.2075, S.987 Protecting Life and Integrity in Research Act of 2025; S.1630, H.R.3235 More Opportunity for Moms to Succeed Act; H.R.4131, S.2172 Respectful Treatment of Unborn Remains Act of 2025; H.R. 685 Support and Value Expectant Moms and Babies Act; Emergency Medical Treatment and Active Labor Act; Dismemberment Abortion Ban Act; IVF Issues; Administration Personnel and Judicial Nominees; Presidential Administration Actions
Client expense: $490,000 · Firm income: Not reported
2025 · second_quarter · Science/Technology
NIH's proposed cap of 15% on F&A expenditures Updates on impacts of Executive Orders and agency directives on U-M operations and funded research projects CREATE AI Act of 2025 (H.R. 2385) Deterrent Act (H.R. 1048) Risky Research Review Act (S. 854/H.R. 1864) Investing in National Next-Generation Opportunities for Venture Acceleration and Technological Excellence (INNOVATE) Act (S. 853) SBIR/STTR reauthorization - potential provisions related to undue foreign influence Policy related to AI research and funding Issues pertaining to science and security National Defense Authorization Act for FY26 (NDAA) H.R. 881 - DHS Restrictions on Confucius Institutes and Chinese Entities of Concern Act H.R. 1082 - Cell and Tissue Product Safety
Client expense: $110,000 · Firm income: Not reported
Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Science Foundation (NSF), Office of Science & Technology Policy (OSTP), SENATE
2025 · second_quarter · Science/Technology
HR 1082, Shandra Eisenga Human Cell and Tissue Product Safety Act
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
Committee Consideration and Mark-up Session Held
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Referred To |
| February 6, 2025 |
| February 6, 2025 |
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Client expense: $490,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office